Vivid S60N, Vivid S70N
GE Medical Systems Ultrasound and Primary Care Diagnostics • Radiology • 07/16/2020
Device Purpose
The Vivid S60N and Vivid S70N are advanced diagnostic ultrasound systems designed for comprehensive imaging, with a primary focus on cardiac applications, utilizing a wide range of transducer technologies and imaging modes. These systems incorporate artificial intelligence for automated measurements and enhanced functional analysis tools for detailed assessment of cardiac chamber mechanics, aiming to improve diagnostic accuracy and workflow efficiency.
Summary
The Vivid S60N and Vivid S70N are general-purpose diagnostic ultrasound systems specialized for cardiac imaging, intended for use by qualified physicians in hospital or private medical office settings. These mobile systems enable ultrasound imaging, measurement, display, and analysis of the human body and fluids through digital acquisition, processing, and a comprehensive user interface including a height-adjustable control panel and color LCD touch screen. They support a broad spectrum of clinical applications such as fetal/obstetrics, abdominal, pediatric, small organ, cephalic, adult and pediatric cardiac, peripheral vascular, musculoskeletal, urology, transesophageal, transvaginal, transrectal, intra-cardiac, intra-luminal, interventional guidance, and intraoperative vascular procedures. The systems employ established ultrasound principles with a variety of electronic array transducers and offer multiple imaging modes including 3D/4D, B-mode, M-mode, various Doppler modalities, Harmonic Imaging, and Coded Pulse. Key technological advancements include AI-driven features for semi-automated 2D cardiac measurements and Doppler spectrum recognition. Enhanced functional imaging tools like AFI 3.0 for left ventricle analysis (compatible with GEHC raw data and third-party DICOM images), Auto EF 3.0 for LV function assessment, AFI RV for right ventricular strain, and AFI LA for left atrial strain and volume analysis are incorporated. Additional features include Launchpad for third-party app integration, HD Color for improved 3D color visualization, DICOM PDF Read capability, and expanded Z-score datasets, all developed under rigorous quality assurance and non-clinical safety testing.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the AI Auto Measure features (both 2D and Spectrum Recognition) compare to manual measurements by experienced sonographers in terms of accuracy and time efficiency across diverse patient populations?; What is the quantitative impact of the HD Color feature on diagnostic confidence and interpretation time for complex 3D cardiac structures compared to standard 3D color rendering?; For the AFI RV and AFI LA modules, what are the validated normal reference ranges, and how do these tools perform in detecting early-stage dysfunction in the right ventricle and left atrium respectively?; What is the interoperability performance of AFI 3.0 and Auto EF 3.0 when analyzing DICOM images from a wide range of third-party ultrasound scanners, particularly concerning variability in image quality and acquisition parameters?; Considering the Launchpad feature for third-party apps, what are the specific qualification and compatibility verification processes, and how is data security and system stability maintained when running these external applications?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly